Diastolic dysfunction laboratory findings

Revision as of 03:58, 21 October 2012 by Shankar Kumar (talk | contribs)
Jump to navigation Jump to search

Diastolic dysfunction Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Causes

Differentiating Diastolic dysfunction from other Diseases

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Echocardiography

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Diastolic dysfunction laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Diastolic dysfunction laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Diastolic dysfunction laboratory findings

CDC on Diastolic dysfunction laboratory findings

Diastolic dysfunction laboratory findings in the news

Blogs on Diastolic dysfunction laboratory findings

Directions to Hospitals Treating Diastolic dysfunction

Risk calculators and risk factors for Diastolic dysfunction laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Laboratory Findings

Plasma brain natriuretic peptide (BNP) or N-terminal pro b-type natriuretic peptide (NT-proBNP) can be used to diagnose heart failure when diagnosis is unclear. The markers have been found to have lower levels in diastolic dysfunction when compared with systolic dysfunction[1]. Suggested partition values for diagnosis of DHF are BNP >100 pg/mL or NT-proBNP >300 pg/mL. In addition, BNP >100 pg/mL and NT-proBNP >300 pg/mL are independent predictors of adverse cardiovascular events in patients with heart failure with preserved left ventricular ejection fraction[2].

References

  1. Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P; et al. (2003). "Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study". J Am Coll Cardiol. 41 (11): 2010–7. PMID 12798574.
  2. Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K; et al. (2008). "Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction". Am J Cardiol. 102 (6): 733–7. doi:10.1016/j.amjcard.2008.04.048. PMID 18773998.

Template:WH Template:WS